1. ？SIEGEL R, NAISHADHAM D, JEMAL A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1):11-30.
[2]
2. AMBROSINI G, ADIDA C, ALTIERI D C. A novel anti-apoptosis gene, survivin, expressed in Cancer and lymphoma[J]. Nat Med, 1997, 3(8):917-921.
[3]
3. XUE Z, SUN P H, ZHU L M, et al. Adeno-associated virus-mediated survivin mutant Thr34Ala cooperates with oxaliplatin to inhibit tumor growth and angiogenesis in colon Cancer[J]. Oncol Rep, 2011, 25(4):1039-1046.
[4]
4. ZHU D E, HOTI N, SONG Z, et al. Suppression of tumor growth using a recombinant adenoviral vector carrying the dominant-negative mutant gene Survivin-D53A in a nude mice model[J]. Cancer Gene Ther, 2006, 13(8):762-770.
[5]
5. DENG H X, JIANG Q Y, YANG Y, et al. Intravenous liposomal delivery of the short hairpin RNAs against Plk1 controls the growth of established human hepatocellular carcinoma[J]. Cancer Biol Ther, 2011, 11(4):401-409.
[6]
6. ALTIERI D C. Survivin and IAP proteins in cell-death mechanisms[J]. Biochem J, 2010, 430(2):199-205.
[7]
7. WANG Y H, ZHU H X, QUAN L P, et al. Downregulation of survivin by RNAi inhibits the growth of esophageal carcinoma cells[J]. Cancer Biol Ther, 2005, 4(9):974-978.
[8]
8. LIU W S, YAN H J, QIN R Y, et al. siRNA directed against survivin enhances pancreatic Cancer cell gemcitabine chemosensitivity[J]. Dig Dis Sci, 2009, 54(1):89-96.
[9]
9. VALJENT E, PASCOLI V, SVENNINGSSON P, et al. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum[J]. Proc Natl Acad Sci U S A, 2005, 102(2):491-496.
[10]
10. NOGUEIRA-FERREIRA R, VITORINO R, FERREIRA-PINTO M J, et al. Exploring the role of post-translational modifications on protein-protein interactions with survivin[J]. Arch Biochem Biophys, 2013, 538(2):64-70.
[11]
11. PANYAM J, LABHASETWAR V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue[J]. Adv Drug Deliv Rev, 2012, 64(S):61-71.
[12]
12. PISSUWAN D, NⅡDOME T, CORTIE M B. The forthcoming applications of Gold nanoparticles in drug and gene delivery systems[J]. J Control Release, 2011, 149(1, SI):65-71.
[13]
13. TROS D C. SUN Y, DUZGUNES N. Gene delivery by lipoplexes and polyplexes[J]. Eur J Pharm Sci, 2010, 40(3):159-170.
[14]
14. CHRISTENSEN C L, GJETTING T, POULSEN T T, et al. Targeted cytosine Deaminase-Uracil phosphoribosyl transferase suicide gene therapy induces small cell lung Cancer-Specific cytotoxicity and tumor growth delay[J]. Clin Cancer Res, 2010, 16(8):2308-2319.
[15]
15. LU C, STEWART D J, JI L, et al. Systemic gene therapy with tumor suppressor FUS1-nanoparticles for recurrent/metastatic lung Cancer[J]. J Clin Oncol, 2010, 28(15):7582.
[16]
16. LU C, STEWART D J, JI L. A phase I trial of intravenous therapy with tumor suppressor FUS1-nanoparticles[J]. J Clin Oncol, 2009, 27(15):e19065.
[17]
17. YANG Y, BAI Y, XIE G, et al. Efficient inhibition of Non-Small-Cell lung Cancer xenograft by systemic delivery of Plasmid-Encoding Short-Hairpin RNA targeting VEGF[J]. Cancer Biother Radiopharm, 2010, 25(1):65-73.
